FDA Approves Enhertu for HER2-Low and HER2-UltraLow Breast Cancer
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody...
Immunophage Partners with GoBroad Cancer Hospital for IPG1094 Phase II Study
Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and...
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...
Haisco’s HSK39004 Gains NMPA Approval for COPD Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
Sino Medical Sciences’ NC Rockstar Catheter Gains MDA Approval in Malaysia
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...
Junshi Biosciences Receives NMPA Approval for JS213 Clinical Trials
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the...
ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...
Becton Dickinson Considers Spinning Off Life Sciences Division
US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...
Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition
Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...
Nona Biosciences Partners with Invetx for Animal Health Therapies
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
Novartis Reports 12% YOY Growth in Full-Year Net Sales
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for...